Literature DB >> 24747161

Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles.

Aaron C Anselmo1, Samir Mitragotri2.   

Abstract

Cellular hitchhiking leverages the use of circulatory cells to enhance the biological outcome of nanoparticle drug delivery systems, which often suffer from poor circulation time and limited targeting. Cellular hitchhiking utilizes the natural abilities of circulatory cells to: (i) navigate the vasculature while avoiding immune system clearance, (ii) remain relatively inert until needed and (iii) perform specific functions, including nutrient delivery to tissues, clearance of pathogens, and immune system surveillance. A variety of synthetic nanoparticles attempt to mimic these functional attributes of circulatory cells for drug delivery purposes. By combining the advantages of circulatory cells and synthetic nanoparticles, many advanced drug delivery systems have been developed that adopt the concept of cellular hitchhiking. Here, we review the development and specific applications of cellular hitchhiking-based drug delivery systems.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Blood; Cell-mediated drug delivery; Cellular hitchhiking; Nanomedicine; Nanoparticles; Nanotechnology

Mesh:

Year:  2014        PMID: 24747161      PMCID: PMC4142097          DOI: 10.1016/j.jconrel.2014.03.050

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  78 in total

1.  Long circulating nanoparticles via adhesion on red blood cells: mechanism and extended circulation.

Authors:  Elizabeth Chambers; Samir Mitragotri
Journal:  Exp Biol Med (Maywood)       Date:  2007-07

Review 2.  Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.

Authors:  Paul J Tacken; I Jolanda M de Vries; Ruurd Torensma; Carl G Figdor
Journal:  Nat Rev Immunol       Date:  2007-10       Impact factor: 53.106

Review 3.  Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities.

Authors:  Zhiliang Cheng; Ajlan Al Zaki; James Z Hui; Vladimir R Muzykantov; Andrew Tsourkas
Journal:  Science       Date:  2012-11-16       Impact factor: 47.728

4.  Engineering antigens for in situ erythrocyte binding induces T-cell deletion.

Authors:  Stephan Kontos; Iraklis C Kourtis; Karen Y Dane; Jeffrey A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

5.  Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes.

Authors:  E T Dams; P Laverman; W J Oyen; G Storm; G L Scherphof; J W van Der Meer; F H Corstens; O C Boerman
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

6.  Cell surface negativity and the binding of positively charged particles.

Authors:  L Weiss; R Zeigel
Journal:  J Cell Physiol       Date:  1971-04       Impact factor: 6.384

7.  A macrophage-nanozyme delivery system for Parkinson's disease.

Authors:  Elena V Batrakova; Shu Li; Ashley D Reynolds; R Lee Mosley; Tatiana K Bronich; Alexander V Kabanov; Howard E Gendelman
Journal:  Bioconjug Chem       Date:  2007-08-31       Impact factor: 4.774

8.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions.

Authors:  Alessandro Parodi; Nicoletta Quattrocchi; Anne L van de Ven; Ciro Chiappini; Michael Evangelopoulos; Jonathan O Martinez; Brandon S Brown; Sm Z Khaled; Iman K Yazdi; Maria Vittoria Enzo; Lucas Isenhart; Mauro Ferrari; Ennio Tasciotti
Journal:  Nat Nanotechnol       Date:  2012-12-16       Impact factor: 39.213

9.  Freely suspended cellular "backpacks" lead to cell aggregate self-assembly.

Authors:  Albert J Swiston; Jonathan B Gilbert; Darrell J Irvine; Robert E Cohen; Michael F Rubner
Journal:  Biomacromolecules       Date:  2010-07-12       Impact factor: 6.988

10.  Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS.

Authors:  Huanyu Dou; Cassi B Grotepas; JoEllyn M McMillan; Christopher J Destache; Mahesh Chaubal; Jane Werling; James Kipp; Barrett Rabinow; Howard E Gendelman
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

View more
  50 in total

Review 1.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

2.  Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.

Authors:  Feihu Wang; Michael Porter; Alexandros Konstantopoulos; Pengcheng Zhang; Honggang Cui
Journal:  J Control Release       Date:  2017-09-25       Impact factor: 9.776

Review 3.  Applying nanomedicine in maladaptive inflammation and angiogenesis.

Authors:  Amr Alaarg; Carlos Pérez-Medina; Josbert M Metselaar; Matthias Nahrendorf; Zahi A Fayad; Gert Storm; Willem J M Mulder
Journal:  Adv Drug Deliv Rev       Date:  2017-05-12       Impact factor: 15.470

Review 4.  Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.

Authors:  Haifa Shen; Tong Sun; Hanh H Hoang; Jana S Burchfield; Gillian F Hamilton; Elizabeth A Mittendorf; Mauro Ferrari
Journal:  Semin Immunol       Date:  2017-09-23       Impact factor: 11.130

Review 5.  Improving cell-based therapies by nanomodification.

Authors:  Wei Chen; Liwu Fu; Xiaoyuan Chen
Journal:  J Control Release       Date:  2015-09-28       Impact factor: 9.776

6.  Nanoparticle uptake by circulating leukocytes: A major barrier to tumor delivery.

Authors:  Jamie L Betker; Dallas Jones; Christine R Childs; Karen M Helm; Kristina Terrell; Maria A Nagel; Thomas J Anchordoquy
Journal:  J Control Release       Date:  2018-07-17       Impact factor: 9.776

Review 7.  Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy.

Authors:  Pedro P G Guimarães; Stephanie Gaglione; Tomasz Sewastianik; Ruben D Carrasco; Robert Langer; Michael J Mitchell
Journal:  ACS Nano       Date:  2018-02-06       Impact factor: 15.881

Review 8.  Non-affinity factors modulating vascular targeting of nano- and microcarriers.

Authors:  Jacob W Myerson; Aaron C Anselmo; Yaling Liu; Samir Mitragotri; David M Eckmann; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2015-10-24       Impact factor: 15.470

Review 9.  Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems.

Authors:  Carlos H Villa; Aaron C Anselmo; Samir Mitragotri; Vladimir Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2016-03-03       Impact factor: 15.470

10.  Nanomedicine-Enabled Modulation of Tumor Hypoxic Microenvironment for Enhanced Cancer Therapy.

Authors:  Jinping Wang; Beilu Zhang; Jingyu Sun; Yuhao Wang; Hongjun Wang
Journal:  Adv Ther (Weinh)       Date:  2019-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.